CCL16	0	5	B-Gene_or_gene_product
activates	6	15	O
an	16	18	O
angiogenic	19	29	O
program	30	37	O
in	38	40	O
vascular	41	49	B-Cell
endothelial	50	61	I-Cell
cells	62	67	I-Cell
.	67	68	O

Besides	70	77	O
regulating	78	88	O
leukocyte	89	98	B-Cell
trafficking	99	110	O
in	111	113	O
normal	114	120	O
and	121	124	O
injured	125	132	O
tissues	133	140	B-Tissue
,	140	141	O
several	142	149	O
chemokines	150	160	O
may	161	164	O
positively	165	175	O
or	176	178	O
negatively	179	189	O
regulate	190	198	O
angiogenesis	199	211	O
.	211	212	O

Here	213	217	O
we	218	220	O
report	221	227	O
that	228	232	O
CCL16	233	238	B-Gene_or_gene_product
activates	239	248	O
an	249	251	O
angiogenic	252	262	O
program	263	270	O
in	271	273	O
vascular	274	282	B-Cell
endothelial	283	294	I-Cell
cells	295	300	I-Cell
by	301	303	O
activating	304	314	O
CCR1	315	319	B-Gene_or_gene_product
.	319	320	O

CCL16	321	326	B-Gene_or_gene_product
induces	327	334	O
dose	335	339	O
-	339	340	O
dependent	340	349	O
random	350	356	O
and	357	360	O
directional	361	372	O
migration	373	382	O
of	383	385	O
endothelial	386	397	B-Cell
cells	398	403	I-Cell
isolated	404	412	O
from	413	417	O
large	418	423	O
vessels	424	431	B-Multi-tissue_structure
and	432	435	O
liver	436	441	B-Tissue
capillaries	442	453	I-Tissue
without	454	461	O
inducing	462	470	O
their	471	476	O
proliferation	477	490	O
.	490	491	O

It	492	494	O
also	495	499	O
promotes	500	508	O
endothelial	509	520	B-Cell
differentiation	521	536	O
into	537	541	O
capillary	542	551	B-Tissue
-	551	552	I-Tissue
like	552	556	I-Tissue
structures	557	567	I-Tissue
in	568	570	O
an	571	573	O
in	574	576	O
vitro	577	582	O
assay	583	588	O
and	589	592	O
is	593	595	O
angiogenic	596	606	O
in	607	609	O
the	610	613	O
chick	614	619	B-Organism
chorionallantoic	620	636	B-Multi-tissue_structure
membrane	637	645	I-Multi-tissue_structure
.	645	646	O

These	647	652	O
angiogenic	653	663	O
activities	664	674	O
are	675	678	O
neutralized	679	690	O
by	691	693	O
a	694	695	O
specific	696	704	O
antibody	705	713	O
against	714	721	O
CCL16	722	727	B-Gene_or_gene_product
.	727	728	O

The	729	732	O
direct	733	739	O
angiogenic	740	750	O
activity	751	759	O
of	760	762	O
CCL16	763	768	B-Gene_or_gene_product
is	769	771	O
further	772	779	O
amplified	780	789	O
by	790	792	O
its	793	796	O
ability	797	804	O
to	805	807	O
prime	808	813	O
endothelium	814	825	B-Tissue
to	826	828	O
a	829	830	O
mitogen	831	838	O
signal	839	845	O
induced	846	853	O
by	854	856	O
vascular	857	865	B-Gene_or_gene_product
endothelial	866	877	I-Gene_or_gene_product
growth	878	884	I-Gene_or_gene_product
factor	885	891	I-Gene_or_gene_product
A	892	893	I-Gene_or_gene_product
and	894	897	O
to	898	900	O
raise	901	906	O
their	907	912	O
basal	913	918	O
production	919	929	O
of	930	932	O
CXCL8	933	938	B-Gene_or_gene_product
and	939	942	O
CCL2	943	947	B-Gene_or_gene_product
,	947	948	O
2	949	950	O
other	951	956	O
angiogenic	957	967	O
chemokines	968	978	O
.	978	979	O

BX471	980	985	B-Drug_or_compound
(	986	987	O
R	987	988	B-Drug_or_compound
-	988	989	I-Drug_or_compound
N	989	990	I-Drug_or_compound
-	990	991	I-Drug_or_compound
[	991	992	I-Drug_or_compound
5	992	993	I-Drug_or_compound
-	993	994	I-Drug_or_compound
chloro	994	1000	I-Drug_or_compound
-	1000	1001	I-Drug_or_compound
2	1001	1002	I-Drug_or_compound
-	1002	1003	I-Drug_or_compound
[	1003	1004	I-Drug_or_compound
2	1004	1005	I-Drug_or_compound
-	1005	1006	I-Drug_or_compound
[	1006	1007	I-Drug_or_compound
4	1007	1008	I-Drug_or_compound
(	1008	1009	I-Drug_or_compound
4	1009	1010	I-Drug_or_compound
-	1010	1011	I-Drug_or_compound
fluorophenyl	1011	1023	I-Drug_or_compound
)	1023	1024	I-Drug_or_compound
methyl	1025	1031	I-Drug_or_compound
]	1031	1032	I-Drug_or_compound
-	1032	1033	I-Drug_or_compound
2	1033	1034	I-Drug_or_compound
-	1034	1035	I-Drug_or_compound
methyl	1035	1041	I-Drug_or_compound
-	1041	1042	I-Drug_or_compound
1	1042	1043	I-Drug_or_compound
-	1043	1044	I-Drug_or_compound
piperazinyl	1044	1055	I-Drug_or_compound
]	1055	1056	I-Drug_or_compound
-	1056	1057	I-Drug_or_compound
2	1057	1058	I-Drug_or_compound
-	1058	1059	I-Drug_or_compound
oxoethoxy	1059	1068	I-Drug_or_compound
]	1068	1069	I-Drug_or_compound
phenyl	1069	1075	I-Drug_or_compound
]	1075	1076	I-Drug_or_compound
urea	1077	1081	I-Drug_or_compound
hydrochloric	1082	1094	I-Drug_or_compound
acid	1095	1099	I-Drug_or_compound
salt	1100	1104	I-Drug_or_compound
)	1104	1105	O
,	1105	1106	O
a	1107	1108	O
CCR1	1109	1113	B-Gene_or_gene_product
antagonist	1114	1124	O
,	1124	1125	O
inhibits	1126	1134	O
angiogenic	1135	1145	O
properties	1146	1156	O
of	1157	1159	O
CCL16	1160	1165	B-Gene_or_gene_product
,	1165	1166	O
whereas	1167	1174	O
blocking	1175	1183	O
of	1184	1186	O
CCR8	1187	1191	B-Gene_or_gene_product
or	1192	1194	O
desensitizing	1195	1208	O
CCR2	1209	1213	B-Gene_or_gene_product
,	1213	1214	O
which	1215	1220	O
are	1221	1224	O
both	1225	1229	O
well	1230	1234	O
known	1235	1240	O
receptors	1241	1250	O
for	1251	1254	O
CCL16	1255	1260	B-Gene_or_gene_product
,	1260	1261	O
did	1262	1265	O
not	1266	1269	O
abolish	1270	1277	O
endothelial	1278	1289	B-Cell
activation	1290	1300	O
.	1300	1301	O

CCL16	1302	1307	B-Gene_or_gene_product
may	1308	1311	O
be	1312	1314	O
specifically	1315	1327	O
cross	1328	1333	O
-	1333	1334	O
linked	1334	1340	O
to	1341	1343	O
CCR1	1344	1348	B-Gene_or_gene_product
expressed	1349	1358	O
on	1359	1361	O
endothelial	1362	1373	B-Cell
cells	1374	1379	I-Cell
.	1379	1380	O

The	1381	1384	O
largely	1385	1392	O
restricted	1393	1403	O
CCL16	1404	1409	B-Gene_or_gene_product
expression	1410	1420	O
in	1421	1423	O
the	1424	1427	O
liver	1428	1433	B-Organ
suggests	1434	1442	O
that	1443	1447	O
this	1448	1452	O
chemokine	1453	1462	O
may	1463	1466	O
play	1467	1471	O
a	1472	1473	O
role	1474	1478	O
in	1479	1481	O
hepatic	1482	1489	O
vascular	1490	1498	B-Multi-tissue_structure
formation	1499	1508	O
during	1509	1515	O
development	1516	1527	O
and	1528	1531	O
in	1532	1534	O
angiogenesis	1535	1547	O
associated	1548	1558	O
to	1559	1561	O
hepatic	1562	1569	O
diseases	1570	1578	O
.	1578	1579	O

